CMLT SEC filings, in plain English
Everything CM Life Sciences III Inc. has filed with the SEC that we hold — 40 filings, newest first, 1 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
combination deadlinenothing moved · 1 with no prior record of ours
- Combination deadline
- 2025-01-31 · unchanged
The clause …“the Company with an option to further extend the lease expiration date to January 31, 2025 if Surface does not provide written notice on or before September 30, 2023 that it will retake possession of the premises on July 31, 2024.”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: EQRx, Inc., the post-combination successor to CM Life Sciences III, and Revolution Medicines, Inc. issued a joint proxy statement and prospectus for the merger agreement dated July 31, 2023. Each EQRx share converts into 7,692,308 Revolution Medicines shares in aggregate plus an additional number determined by dividing $870,000,000 by the daily volume weighted average closing price of Revolution Medicines stock multiplied by 0.94. Why it matters: The $870,000,000 component is fixed in dollars and divided by Revolution Medicines' own share price, so EQRx holders receive more shares if RVMD falls and fewer if it rises — the dollar value of that slice is protected, unlike a fixed exchange ratio. The 0.94 multiplier is a 6% haircut applied to the reference price. With 497 million EQRx shares outstanding, exchange ratios of 0.0734 to 0.0841 quantify how little each share is worth in the combination.
combination deadlinenothing moved · 1 with no prior record of ours
- Combination deadline
- 2025-01-31 · unchanged
The clause …“the Company with an option to further extend the lease expiration date to January 31, 2025 if Surface does not provide written notice on or before September 30, 2023 that it will retake possession of the premises on July 31, 2024.”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.